UB Paderborn / Katalog / Suche / in CDI

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

The lancet oncology, 2014, Vol.15 (1), p.59-68

2014

Volltextzugriff (PDF)

Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma

American journal of respiratory and critical care medicine, 2010-03, Vol.181 (6), p.620-625

2010

Volltextzugriff (PDF)

Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma

Journal of thoracic oncology, 2011-11, Vol.6 (11), p.1930-1937

2011

Volltextzugriff (PDF)

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)

PloS one, 2016-03, Vol.11 (3), p.e0147599-e0147599

2016

Volltextzugriff (PDF)

Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-Exposed Individuals: A Prospective Longitudinal Cohort Study

Journal of thoracic oncology, 2011-05, Vol.6 (5), p.889-895

2011

Volltextzugriff (PDF)

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7500-7500

2013

Volltextzugriff (PDF)

The Effect of Clinical Covariates on the Diagnostic and Prognostic Value of Soluble Mesothelin and Megakaryocyte Potentiating Factor

Chest, 2012-02, Vol.141 (2), p.477-484

2012

Volltextzugriff (PDF)

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer

Journal of thoracic oncology, 2015-10, Vol.10 (10), p.1458-1467

2015

Volltextzugriff (PDF)

Abrupt Severe Chest Pain and Vomiting: Remember to Think of a Ruptured Oesophagus (Boerhaave Syndrome)

European journal of case reports in internal medicine, 2019, Vol.6 (10), p.001265-001265

2019

Volltextzugriff (PDF)

Abstracts book

Acta clinica belgica (English ed. Online), 2020, Vol.75 (sup1), p.1-41

Van De Voorde, Patrick

2020

Volltextzugriff (PDF)

Increased IL-6 and TGF-β1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy

International journal of radiation oncology, biology, physics, 2004-03, Vol.58 (3), p.758-767

2004

Volltextzugriff (PDF)

Measles-induced Acute Disseminated Encephalomyelitis in a Non-vaccinated Patient

European journal of case reports in internal medicine, 2020-04, Vol.7 (6), p.001332

2020

Volltextzugriff (PDF)

The Importance of Accurate Lymph Node Staging in Early and Locally Advanced Non-small Cell Lung Cancer: An Update on Available Techniques

Journal of thoracic oncology, 2007-06, Vol.2 (6), p.S59-S67

2007

Volltextzugriff (PDF)

Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer

PloS one, 2016-03, Vol.11 (3)

2016

Volltextzugriff (PDF)

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062

European journal of cancer (1990), 2011-10, Vol.47 (15), p.2322-2330

2011

Volltextzugriff (PDF)

European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer

Clinical cancer research, 2003-01, Vol.9 (1), p.143-150

2003

Volltextzugriff (PDF)

GAIN-(L): Efficacy and biomarker findings of RG7160 (GA201), a novel, dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with first-line cisplatin and pemetrexed in metastatic nonsquamous NSCLC

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7544-7544

2012

Volltextzugriff (PDF)

Prise en charge du cancer pulmonaire non à petites cellules

Revue médicale suisse, 2007, Vol.3 (122), p.1890-1895

2007

Volltextzugriff (PDF)

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2017-02, Vol.12 (2), p.383-389

2017

Volltextzugriff (PDF)

Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine

Lung cancer (Amsterdam, Netherlands), 2003-05, Vol.40 (2), p.191-199

2003

Volltextzugriff (PDF)

Measles-induced Acute Disseminated Encephalomyelitis in a Non-vaccinated Patient

European journal of case reports in internal medicine, 2020-04, Vol.7 (6), p.001332-001332

2020

Volltextzugriff (PDF)

An unusual cause of portal hypertension in a cirrhotic patient

International Journal of Medical Reviews and Case Reports, 2019-10, p.1

2019

Volltextzugriff (PDF)

An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2013-12, Vol.8 (12), p.1529-1537

2013

Volltextzugriff (PDF)

Headaches after a recent pregnancy need an MRI to rule out cerebral thrombosis

International Journal of Medical Reviews and Case Reports, 2019, p.1

2019

Volltextzugriff (PDF)

Mediastinal cystic lesions: a rare entity

International Journal of Medical Reviews and Case Reports, 2019, p.1

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma

Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)

Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-Exposed Individuals: A Prospective Longitudinal Cohort Study

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer

The Effect of Clinical Covariates on the Diagnostic and Prognostic Value of Soluble Mesothelin and Megakaryocyte Potentiating Factor

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer

Abrupt Severe Chest Pain and Vomiting: Remember to Think of a Ruptured Oesophagus (Boerhaave Syndrome)

Abstracts book

Increased IL-6 and TGF-β1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy

Measles-induced Acute Disseminated Encephalomyelitis in a Non-vaccinated Patient

The Importance of Accurate Lymph Node Staging in Early and Locally Advanced Non-small Cell Lung Cancer: An Update on Available Techniques

Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062

European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer

GAIN-(L): Efficacy and biomarker findings of RG7160 (GA201), a novel, dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with first-line cisplatin and pemetrexed in metastatic nonsquamous NSCLC

Prise en charge du cancer pulmonaire non à petites cellules

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer

Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine

Measles-induced Acute Disseminated Encephalomyelitis in a Non-vaccinated Patient

An unusual cause of portal hypertension in a cirrhotic patient

An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer

Headaches after a recent pregnancy need an MRI to rule out cerebral thrombosis

Mediastinal cystic lesions: a rare entity

Suchergebnisse filtern